STOCKS TELEGRAPH

Tag: Biotech Stocks

  • Top Biotech Stocks Set to Move in 2026

    Top Biotech Stocks Set to Move in 2026

    Key Takeaways

    • Novavax, Inc. (NASDAQ: NVAX) stock has shifted from vaccine manufacturing to a high-margin licensing model built around proprietary technology.
    • Grace Therapeutics, Inc. (NASDAQ: GRCE) stock is approaching a major FDA decision that could redefine its valuation.
    • Both companies represent a new generation of biotech stocks focused on capital efficiency rather than lab-scale expansion.
    • Novavax offers recurring royalty potential, while Grace provides catalyst-driven upside tied to rare-disease treatments.
    • These stocks highlight how the biotech sector is rewarding strategic pivots over speculative research.

    Introduction

    Biotech stocks are entering a more disciplined phase. The market is no longer rewarding companies for scale alone or pandemic-era urgency. Instead, investors are focusing on sustainability, capital efficiency, and clear paths to monetization.

    As healthcare budgets tighten and regulatory scrutiny increases, biotechnology companies must prove they can generate value beyond experimental pipelines. This environment favors firms that either monetize proprietary platforms through licensing or target high-need medical conditions with efficient regulatory pathways.

    Novavax and Grace Therapeutics reflect this evolution. Each has reshaped its strategy to align with long-term commercial realities rather than short-term hype.

    What Defines Modern Biotech Stocks

    Modern biotech stocks often look very different from their predecessors. Instead of large manufacturing footprints or sprawling research teams, many now rely on partnerships, licensing agreements, and asset-light operations.

    Common traits include:

    • Platform technologies licensed to larger partners
    • Focus on niche or orphan indications
    • Lower fixed costs and reduced cash burn
    • Clear regulatory milestones

    This shift allows smaller biotech firms to survive longer and capture value without constant shareholder dilution.

    Why Investors Are Re-Evaluating the Biotechnology Sector

    Investor sentiment toward biotech has changed significantly since the pandemic. Valuations have compressed, capital has become more selective, and profitability timelines matter more than ever.

    Companies that can demonstrate revenue visibility, partnership validation, or near-term regulatory catalysts are increasingly favored. This environment benefits biotech stocks that can show commercial discipline alongside scientific credibility.

    Key Drivers, Risks, and Industry Trends

    Licensing-Driven Business Models

    Licensing allows biotech companies to monetize intellectual property without absorbing the cost of commercialization. Royalty-based revenue can provide long-term cash flow with lower operational risk.

    Rare Disease Focus and Regulatory Efficiency

    Targeting orphan diseases often comes with regulatory advantages, including expedited review pathways and extended market exclusivity. These incentives can significantly improve risk-adjusted returns.

    Risks to Consider

    Despite improved discipline, biotech stocks remain sensitive to regulatory outcomes, funding conditions, and execution risk. Single-asset companies, in particular, can experience sharp valuation swings.

    Novavax, Inc. (NVAX)

    Company Overview and Business Model

    Novavax, Inc. (NVAX) is a biotechnology company that has transformed itself from a vaccine manufacturer into a licensing-focused platform business. Its core asset is the Matrix-M adjuvant, a proprietary technology that enhances immune responses in protein-based vaccines.

    Novavax now positions itself as a technology provider rather than a direct competitor, allowing larger pharmaceutical partners to handle manufacturing and commercialization.

    Financial Performance and Strategic Developments

    Novavax has aggressively reduced operating expenses and consolidated facilities to preserve cash. Its recent licensing agreements with Sanofi and Pfizer have shifted revenue toward upfront payments, milestones, and long-term royalties.

    Although NVAX stock is still associated with near-term losses, much of the recent impact has come from non-cash charges rather than operational weakness. The company has significantly improved its cash runway without resorting to dilutive financing.

    Valuation and Analyst Views

    NVAX trades well below its historical levels, reflecting investor skepticism rather than balance sheet distress. Analysts increasingly view the stock as a turnaround play supported by validated technology and blue-chip partnerships.

    Price targets imply meaningful upside if licensing revenue continues to materialize as expected.

    Investment Suitability

    Novavax may suit investors seeking biotech stocks with reduced manufacturing risk and recurring revenue potential. Its licensing-heavy model offers a different risk profile than traditional development-stage biotechs.

    Grace Therapeutics, Inc. (GRCE)

    Company Overview and Business Model

    Grace Therapeutics, Inc. (GRCE) is a late-stage biopharmaceutical company focused on improving existing drugs through proprietary delivery technologies. Grace targets rare and orphan diseases using the FDA’s 505(b)(2) pathway, which reduces development time and cost.

    The company’s lean structure allows it to operate with minimal overhead while advancing clinical programs.

    Financial Performance and Strategic Developments

    Grace currently generates no revenue, which is typical for a late-stage biotech awaiting its first approval. Its cash position is designed to support operations through a critical regulatory window.

    The most significant catalyst for GRCE stock is the FDA’s upcoming decision on GTx-104, a treatment for subarachnoid hemorrhage. This represents a large market opportunity with limited competition.

    Valuation and Analyst Views

    With a relatively small market capitalization, Grace is valued primarily on the probability of regulatory success. Analysts covering the stock maintain optimistic views, citing strong intellectual property protection and orphan drug exclusivity.

    Price targets suggest substantial upside if FDA approval is granted.

    Investment Suitability

    Grace Therapeutics is best suited for aggressive investors comfortable with binary outcomes. Its valuation could change dramatically based on a single regulatory decision.

    Investment Strategies for Biotech Stocks

    A diversified approach is often essential when investing in biotech stocks. Balancing platform-based companies like Novavax with catalyst-driven names like Grace can help manage risk.

    Long-term investors may favor businesses with recurring revenue or licensing income, while shorter-term participants often focus on regulatory milestones. Position sizing and patience are critical given the sector’s volatility.

    Conclusion

    The biotech sector is no longer driven solely by scientific ambition. Commercial discipline, regulatory clarity, and capital efficiency are increasingly defining success.

    Novavax demonstrates how proprietary technology can be monetized through partnerships and royalties. Grace Therapeutics highlights the potential of focused, late-stage development aimed at unmet medical needs.

    Together, these companies illustrate how biotech stocks are evolving from speculative experiments into strategic components of long-term, sector-focused portfolios.

  • What Are Biotech Stocks And How To Invest In Them

    What Are Biotech Stocks And How To Invest In Them

    In this article, we are going to help you understand everything there is about biotech companies ranging from what they are- all the way to- how to invest in biotech stocks. This will help you hit the nail on the head with the trend analysis and strategically make investments in this type of stock.

    Biotech stocks have been in the public’s portfolio right since the inception of the stock market and exchange platforms. But just like the recent surge in Green Energy stocks, EV stocks, and Crypto stocks, we are seeing a new rise and shift in the Biotech stocks’ popularity.

    This both excites the investors as well as creates curiosity over what actually is prompting the rise in biotech company stocks and biotech stock prices. This curiosity is essential for looking into the reasons why the Biotech stocks are trending and analyzing the patterns which are making this type of stock boom. This gives investors and stock analysts an edge in predicting and identifying signals and hints in the market shifts due to internal and external reasons.

    What are biotech stocks?

    Biotech Stocks are essentially publicly traded companies that focus on the development, production, and commercialization of pharmaceutical products and services that are used in the treatment of diseases. The therapeutics and treatments that you consume or apply in daily life, acquiring from pharmacies or hospital dispensaries exist because a Biotech company developed them.

    From a stock perspective, the biotech stock value ranges from triple-digit share prices all the way to under $1 price per share. The ones that are under $5 share prices are known as biotech penny stocks. These, just like every other penny stock are attributed to a lot of volatility however Biotech stocks have their own intrinsic share of volatility and risks (which come along with rewarding outcomes as well). Before we get into that let us first explain what really is creating the hype in this kind of stock, in the first place.

    How Biotech Industry became very popular among investors

    We mentioned before that the trend in the biotech stock is growing as it is in Green energy, Crypto, and EV stocks. But the reason behind this trend is completely different and associated to unique factors.

    Covid-19 Pandemic

    One major reason for the rise is the COVID-19 pandemic, specifically the race for vaccine production. When the pandemic had gripped the world in its virus, it had paralyzed many markets and business; the overall global economy was halted. In fact, even the most successful biotech companies had been forced to shut down. But Pandemic being human health and medical crisis had prompted responses from the very biotech industry that it had halted. The Biotech industry decided to push for solutions to the Pandemic and the virus, in the form of Vaccines. The vaccines became a huge market space in the healthcare industry and biotech stocks immediately started filling it up.

    The aging population

    According to the Rural Health Information Hub, The US population has more than 46 million citizens above or at the age of 65 which is expected to grow to 90 million almost in 2050. Every one in five Americans will be aged over 65 years old. The context of this is important when you correlate the use of prescribed medicines and drugs with old age; the older population uses prescribed medicines and drugs more often to treat their chronic illnesses and complications, as compared to younger generations. This means demand and innovation required from the Biotech Companies will increment in the following years and push the companies to focus on targeting innovative and niche spaces in the pharmaceutical market as competition concentrate between biotech companies.

    Exposure to Biotech stock

    The former factor is a more prevalent cause of exposure in the biotech market in the current market trend than the latter because the US and the overall world economy is slowly coming out of the Pandemic and rolling out vaccines. The pandemic had crippled many portfolios for the investors in various stocks and companies. During this time, the biotech stock was prevailing due to public, government, and private investors nudging the biotech companies to create vaccinations. This made investment profiles in the Biotech stock especially the ones in the vaccination race, more attractive.

    What are the types of Biotech Stocks?

    Now that we have established the roots of the developing trend in the Biotech industry, let’s focus on what exactly are the cues to look for when you are investing in the Biotech companies stock.

    There are three main types of Biotechnology companies; Medical, Agriculture, and industrial ( or referred to as Red, Green, and White respectively).

    The primary thing to focus on when you invest in Biotech companies is to have a bird’s eye view of all the metric and indicator for the stages and process that are related to Biotech stock’s operations/performances. This helps ensure, that your investment decision is based on solid evidence that can hopefully turn out to be incredibly rewarding.

    Biotech operations and drug development, especially in the Medical type, goes through rigorous testing that are subject to stringent approvals and regulatory standards. These operations, based on the development and approval are broken down into 5 stages.

    Investment and the five stages of Biotech Stock operations

    The first stage of drug development is known as Research and Discovery, where concepts and theories of new products are formed along with a given conceptual framework to back up the attributes and potential of the new product.

    The second stage is known as Preclinical Stage, where the drug’s pharmacological profile is created to assess the strategies and planning of human testing and effects that are expected to result from the early and late clinical stages. This profile is assessed by the regulatory bodies like the US FDA, to be approved and taken to the next stage human trials and tests. These trials and tests take place in 4 phases;

    • Phase 1: The safety of the drug is evaluated in human trials with determination to predict dosage range.
    • Phase 2: The efficacy of the drug is tested relevant to the disease it is targeting. This phase is known as proof of concept (PoC).
    • Phase 3: The proof of concept and previous phases are tested again in large population batches with several thousand people. This phase is known as regulatory proof which when approved requires the next step of New Drug Application (NDA) approval in order for the drug to be marketed.
    • Phase 4: Once the drug is marketed, the companies voluntarily or as per the requirement of the FDA will undertake post approval studies to validate and add additional information about the drug’s safety and efficacy.

    The third stage is known as Early-clinical stage in which the companies start initiating the phases of the testing and study. The first two phases mentioned above are what comes into this stage of Biotech companies. These companies that are in the first two phases are known as Early-stage biotech companies.

    The fourth stage is known as the late-clinical stage and the company is known as late-stage biotech. This stage consists of the regulatory approvals and NDA signing of the drug from the FDA.

    The fifth and final stage is the Commercial Stage, in which the companies have been approved for the NDA and begin rolling out the commercial strategies for the market. This stage also includes Phase 4 study as per requirement or voluntary basis.

    How to Invest in Biotech Stocks

    It may click to you up till this point that the biotechnology companies out there are in different stages of the Biotech lifecycle and thus have different risks associated with each stage for investment. The more progressed and approved the company is, in its stages, the more profitable and attractive its stock looks- however it still remains risky. Biotech Industry Organization (BIO) researched that the likelihood of success and regulatory approval to be received for a company from Phase I to Commercial stage has been 9.6% from data stretching 2006-2015. However, in the 2011-2020 data study, it was reduced to 7.9% which is mainly attributed to the concentration and new entrants in the market.

    The report also showed that even the hottest areas of a biotech investment portfolio which are Neurology, Cardiovascular, and Oncology have an approval rate of 8.4%, 6.6%, and 5.5% respectively. This report was also discussed by the Motley Fools team on their Youtube Channel in which they broke down the approval and success rating according to phases 1 to 4 (Commercialization), which was 70%, 33%, 30%, and less than 10% respectively.

    Failure is the big bad wolf in the biotech stock investment

    The investors need to lookout for the stage that the companies are in, in order to assess if the Biotechnology Company is worth investing into. Furthermore, it is important to heed for investors that companies can fail at any one of these stages which is what makes Biotech stocks volatile and risky. However, while looking into the track record of previous drug approvals of the company as well as the financials of the company, you can make a strong investment. The opposite is also true, once the company has been approved for any one of these stages and progresses, the stock price shoots up to double and triple digit percentages, while in some cases it can shoot up to quadruple digit percentages!

    Other proven ways to invest in Biotech Stock

    Looking at one biotech company’s stock for investment may seem to be tricky sometime, if there aren’t enough indicators to decide if the stock is valuable or not. In cases like these, especially if you are a new investor looking for exposure into the Biotech Industry, the safest bet is to opt for Exchange Traded Funds (ETFs) for biotechnology stocks. Biotech ETFs provide a great space for a new investor to get an exposure into Biotech stocks. Depending on your curiosity and preference you may opt for an equal-holding weight ETF or a market weighted ETF. The former will give you equal exposure to small new biotech stocks as you would get from big blue chip Biotech stocks.

    Another great strategy that has been evolving in the Biotech stock investment is the focus on Contract Research Organizations. Many Biotech stocks discover an idea for their drug candidate and then proceed to outsource the administrative, regulatory, experimentation, and clinical procedures to a CRO which is well equipped for exactly this sort of specialization in the Biotech space. These CROs generate revenue for their services despite the approval or disapproval of the product in any of the stages. Furthermore, big-fish CROs focus on the M&A action where they realize the potential of a new product candidate for which it merges, acquires or partners with the product’s Biotech company and reaps the gains from owning the candidate through its development and approvals. Therefore, investing in Biotech CROs may prove to be a better investment than just the developing Biotech Companies.

    Biotech Penny Stocks under $1

    A great way to start exposing yourself to Biotech stocks is to find biotech penny stocks which are $1 or under. Usually, investors invest in multiple under $1 portfolios to broaden their exposure. Here is a list of Biotech Penny stocks under $1.

    Ticker Company Market Cap Performance (YTD) Price Change
    AEZS Aeterna Zentaris Inc. 109.74 106.82% 0.88 2.11%
    ACST Acasti Pharma Inc. 116.17 71.54% 0.56 -1.24%
    ADXS Advaxis, Inc. 85.82 66.91% 0.58 23.31%
    ZSAN Zosano Pharma Corporation 95.38 64.01% 0.86 -3.94%
    OGEN Oragenics, Inc. 78.24 48.33% 0.67 -1.33%

    Biotech Stocks under $5

    Similarly, if you want to upgrade your investment portfolio from $1 biotech stocks, investors opt for bigger share price and market cap range for their portfolio and as such, focus on $5 or under Biotech stocks to invest in. This adds slightly more reward and risk but still provides great exposure.

    Ticker Company Market Cap Performance (YTD) Price Change
    SESN Sesen Bio, Inc. 755.67 203.70% 4.10 -3.53%
    PTIX Protagenic Therapeutics, Inc. 38.77 152.38% 2.65 -1.85%
    CTXR Citius Pharmaceuticals, Inc. 353.83 111.76% 2.16 0.47%
    MRKR Marker Therapeutics, Inc. 234.82 89.66% 2.75 -1.79%
    OTLK Outlook Therapeutics, Inc. 441.29 86.15% 2.42 1.68%
  • 7 Biotech Stocks to Buy in 2021

    7 Biotech Stocks to Buy in 2021

    Change is inevitable in every aspect of life because it results from human exploration and applying knowledge to improve life quality. This is why many industries have shown significant growth with time, and the biotech industry is one of them. The biotech industry has extraordinarily impacted healthcare, biological science, economy, and business in recent years. The plethora of biotech stocks continuously put their efforts into developing therapeutics and vaccines that are effective and less toxic, and easily accessible for individuals. With the rise of COVID-19, the Biotech industry has gained more importance. Many biotech stocks have developed and commercialize vaccines in the battle against the deadly pandemic. Now many investors are looking for biotech stocks to get high profits in the future. Here are the 7 biotech stocks to buy in 2021.

    Pfizer (PFE)

    The first and foremost stock to watch in 2021 is Pfizer (PFE), one of the first biotech stocks to market the COVID-19 vaccine. Since then, it has contracted with many governments and supplied millions of doses and looking forward to providing more than this in the future. The U.S government has a plan to vaccinate all of its adult population, and Pfizer is likely to contribute a lot to this cause. While many other biotech stocks only focus on older patients, Pfizer is also developing a COVID-19 vaccine for children, which is another positive sign for future growth. The company has a market cap of more than $220 billion and annual revenue of more than $40 billion. Hence Pfizer stock can be a good bet in 2021. 

    Regeneron Pharmaceuticals (REGN)

    The second stock that could prove fruitful for investors in 2021 is Regeneron Pharmaceuticals(REGN). The company has a market cap of more than $55 billion and is engaged in discovering, developing, and manufacturing various therapeutics to treat medical conditions worldwide. One of the two authorized antibody treatments to treat COVID patients belongs to Regeneron. Its recent first-quarter results show that its quarterly revenue showed 38% growth year over year. Its COVID-19 antibody treatment alone generated $262 million in the first quarter of 2021. Besides this, Eylea, a drug to treat eye diseases, also impacts its increased sales over time. Hereafter, investors need to keep an eye on this stock.

    Novavax (NVAX)

    On Number three, we have Novavax (NVAX). It is another biotech stock engaged in the development of commercialization of vaccines to prevent infectious diseases. Novavax has significantly outperformed in the COVID-19 era and still giving a tough time to its competitors. Its COVID-19 vaccine candidate NVX-CoV2373 could bring massive profits in the future. Novavax is about to finalize the major supply deal with the European Union, which means the supply of 500 million or more doses. So, a lot of money on the line is expected for Novavax stock. 

    Moreover, it has also inked supply deals with many countries in which India is also included, which has more than 1.3 billion population. Novavax generated a breathtaking $447 million in revenue in the first quarter of 2021 compared to $3 million in the same quarter of last year. This significantly increased revenue shows its success over the year. In a nutshell, investors should keep an eye on this stock.

    Bio N Tech SE (BNTX)

    On Number four, we have Bio N Tech (BNTX), which is a biotechnology company engaged in discovering and developing therapeutics to treat various infectious diseases. Bio N Tech is the partner of Pfizer in the battle against COVID-19. BNTX stock expects $26 billion in sales for the COVID-19 vaccine and its partner in 2021 and estimates roughly $3 billion in earnings. Millions of the mutually prepared COVID-19 vaccine doses have been delivered to many countries so far. Both partners are negotiating with many other countries to supply COVID-19 vaccine doses worth $3 billion by 2022, which points to the bright future of BioNTech stock. So it can be a good bet for investors in the future.

    Ocugen (OCGN)

    Ocugen (OCGN), stands at number five on our list. It is a clinical-stage biopharmaceutical company focused on developing therapeutics to cure blindness and other retinal diseases. Ocugen stock is working with Bharat Biotech to develop COVAXIN and the vaccine used to treat COVID patients. The phase-3 study results of COVIXIN showed 100% efficacy against severe coronavirus and 78% efficacy against mild and moderate COVID-19 disease. The Indian government has given emergency use authorization to Bharat Biotech which is a positive sign for Ocugen stock. Ocugen stock is looking forward to developing the COVID-19 vaccine for other markets and can be a good bet for investors in the future.

    Seagen (SGEN) 

    Seagen Inc is an American-based biotech stock focused on developing and commercializing therapeutics to treat cancer patients, and it’s in the Number six position on our list. Seagen has shown significant growth in 2020 as compared to 2019. Its revenue for 2020 totaled $2.2 billion, which shows 140% growth over the year. The revenue for the year 2019 was $916.7 billion. The company has achieved global success with Adcetris, an antibody medicine used to treat lymphoma, and is in an excellent position to invest more in developing newer medications. Therefore, Seagen is one of the biotech stocks to watch in 2021.

    Vertex Pharmaceuticals (VRTX)

    The seventh biotech stock to watch in 2021 is Vertex Pharmaceuticals Incorporated (VRTX), which is mainly focused on developing and commercializing therapeutics to treat cystic fibrosis. Trikafta is the most important drug of Vertex pharmaceutical that treats roughly 90% of patients with cystic fibrosis. Estimates show that 70,000 cystic fibrosis patients are there globally, and Trikafta is the only medication available for this disease. Vertex stock has generated significant revenue through Trikafta and some other products, which will continue to rise in the future. The company has partnered with CRISPR Therapeutics and announced impressive results from a clinical trial of gene therapy for two rare blood diseases. Consequently, its continued success against cystic fibrosis and clinical developments suggests that this stock could outperform in the long run.

    The following three biotech stocks are with the lowest 12-month trailing price-to-earnings ‎ratio (P/E). Dividends and buybacks are two ways a company can return profits to ‎shareholders, so a low P/E ratio shows you are paying less for every dollar of profits ‎generated.

    The Agios Pharmaceuticals (AGIO)‎

    The Agios Pharmaceuticals Inc. platform is a pharmaceutical company dedicated to ‎developing drugs for genetic diseases such as hemolytic anemias and sickle cell disease. In Q1 ‎‎2021, the company reported a net income of $1.9 billion, a far cry from its Q1 2020 loss. ‎Agios’ oncology portfolio was sold to Servier Pharmaceuticals LLC in the first quarter, which ‎had an impact on revenue.

    Sage Therapeutics, Inc.. (SAGE)

    Sage Therapeutics has developed treatment for issues related the central nervous system, including schizophrenia and major depression. The company reported positive results from its SAGE-718 clinical trial, a drug that may be used to treat Huntington disease, in Q1 2021.

    Innoviva Inc. (INVA)

    Innoviva is a healthcare-oriented asset manager that holds portfolios of royalties for many pharmaceuticals.

  • 3 of the Best Biotech Stocks to Buy for 2021

    3 of the Best Biotech Stocks to Buy for 2021

    Due to the spread of the coronavirus pandemic all over the world Biotech stocks have gained great attention in the market. There is great competition between biotech giants, and this makes investors confuse to predict which stock will be more fruitful for them in terms of revenue. But one should not ignore the fact that other diseases and medical challenges still exist even if they are not like that much popular as the COVID-19 is.

    Moderna Inc (NASDAQ: MRNA)

    Moderna, Inc. (MRNA) is a leading mRNA Technology platform that aims on using messenger RNA (mRNA) to produce a new generation of transformative drugs for patients.

    2020 proved to be a good year for Moderna because its share price has reached up to the mark of more than 500%.Covid-19 mRNA-1273 is mainly responsible for this rise as this vaccine has shown very effective results. Further this vaccine has gained the trust of about 30 countries’ regulatory bodies as they have approved it for use.

    According to MichaelYee, a Wall Street analyst, Moderna has already signed $11.7B in contracts in which dose range is from 510M to 525M. The company is looking forward to signing additional contracts for 2021 and 2022 where the capacity will reach up to 1.2B doses.

    Moderna has to compete with its competitors especially Pfizer and JNJ(which is going to share results 3rd trial phase of Covid-19 Vaccine shortly) to maintain its reputation but due to the very high demand for vaccine in the globe, at least five companies can sell at full capacity to fulfill the need of vaccine in the globe. Moderna has also stepped in the 2nd phase study of the age group from 12 to 17 and U.S. Food and Drug may authorize vaccine for teens which could add more value to Moderna’sannual revenue.

    Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

    Vertex Pharmaceutics Inc.(VRTX) is focused on discovering, developing & manufacturing small molecule drugs for the cure of cystic fibrosis, viral infections, bacterial infections, autoimmune diseases, cancer, and neurological disorders.

    The company is playing the lead role in the cure of cystic fibrosis as it is estimated that 50% of patients diagnosed with cystic fibrosis in many countries are using Vertex’s medications. Vertex’s main product is Trikafta which is approved by the FDA at the end of 2019. Trikafta has already generated $3b revenue alone and is expected to generate more in the future as the company is putting serious effort to get the approval of this product for different age groups.

    Novavax, Inc. (NASDAQ: NVAX)

    Novavax, Inc. (NVAX) is a late-stage company that aims in improved global health through the discovery, development, and commercialization of innovative vaccines to prevent infectious disease. The company’s main contributions in preventing diseases include COVID-19, seasonal influenza, RSV, Ebola, Mers, and SARS.

    The company has recently announced that it has contracted with the Government of Canada to supply 76Million doses of NVX-CoV2373, a company’s recombinant protein-based COVID-19 vaccine, to control the pandemic in the region. This contract will help the company to generate a handsome revenue in future.

    Besides the COVID-19 vaccine, the company is putting some serious effort into Nanoflu, a seasonal influenza vaccine for the olders, to influence the global influenza market which will worth more than 6Billion annually by 2026. The 3rd clinical analysis of the Nanoflu showed exceptional results and now the company is expecting to get approval from the U.S food and drug administration soon to commercialize its product and if it happens, it will further boost the company’s reputation and maximize the potential to generate billions of dollars revenue annually.

  • 15 Trending Stocks in Biotechnology Industry

    15 Trending Stocks in Biotechnology Industry

    The biggest movers of the 2020 are biotech stocks. Now, the COVID-19 pandemic has put brighter spotlight on the future of healthcare and specially biotech stocks have respond accordingly.

    Innovative biotech business have adopted the change and are competing to make what could become a life-saving treatment for millions in the form of a vaccine.

    Some of the biggest winners of this transformative mega-trend are discussed below.

    Genocea Biosciences Inc. (NASDAQ:GNCA) shares were trading up 24.44% at $4.48 at the time of writing on Friday.

    Genocea Biosciences Inc. (NASDAQ:GNCA) share price went from a low point around $1.10 to briefly over $3.86 in past 52 weeks, though shares have since pulled back to $4.48. GNCA market cap has remained high, hitting $99.50M at the time of writing, giving it price-to-sales ratio of more than 110.

    If we look at the recent analyst rating GNCA, SVB Leerink initiated coverage on GNCA shares with an Outperform.

    Arbutus Biopharma Corporation (ABUS) last closed at $4.96, in a 52-week range of $0.82 to $6.48. Analysts have a consensus price target of $5.00.

    Ocugen Inc. (OCGN) stock soar by 32.85% to $0.38.

    Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Shares headed falling, lower as much as -3.97%. The most recent rating by ROTH Capital, on April 18, 2019, is at a Buy.

    Capricor Therapeutics Inc. (NASDAQ:CAPR) rose 29.31% after gaining more than $1.75 on Friday.

    Ampio Pharmaceuticals Inc. (AMPE) last closed at $0.96, in a 52-week range of $0.26 to $0.97.

    iBio Inc. (IBIO) last closed at $5.50, in a 52-week range of $0.05 to $7.45.

    Novan Inc. (NOVN) stock soar by 6.06% to $0.86. The most recent rating by Piper Jaffray, on January 06, 2020, is at a Neutral.

    Onconova Therapeutics Inc. (NASDAQ:ONTX) Shares headed falling, lower as much as -2.63%. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy.

    Actinium Pharmaceuticals Inc. (AMEX:ATNM) rose 7.45% after gaining more than $0.03 on Friday.

    Sesen Bio Inc. (SESN) last closed at $0.99, in a 52-week range of $0.37 to $1.54.

    VistaGen Therapeutics Inc. (VTGN) stock drop by -4.39% to $0.76. The most recent rating by Maxim Group, on June 27, 2018, is at a Buy.

    Qualigen Therapeutics Inc. (NASDAQ:QLGN) Shares headed rising, higher as much as 11.22%.

    PolarityTE Inc. (NASDAQ:PTE) rose 10.56% after gaining more than $0.17 on Friday.

    Matinas BioPharma Holdings Inc. (MTNB) last closed at $0.96, in a 52-week range of $0.49 to $2.49.